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Drug-induced prolongation of the QT interval has
become a major safety concern during drug development.
Duramycin, a peptide antibiotic, is in clinical develop-
ment for the treatment of cystic fibrosis. It becomes
deposited in cellular membranes where it binds to phos-
phatidylethanolamine. Duramycin may thereby change
biophysical membrane properties and perturb ion chan-
nel function. Thus, its application possibly carries the risk
to elicit a QT-prolongation. Here, we tested the effects of
duramycin on currents through voltage-gated hERG
potassium, sodium and calcium channels of various
mammalian cell types in whole cell patch clamp studies.
We found that duramycin bath concentrations between 1
nM and 0.1 μM did not generate any effects on these cur-
rents. Concentrations ≥0.3 μM, however, reduced the
amplitudes of all the investigated currents. Moreover,
sodium current fast inactivation kinetics was slowed in
the presence of duramycin. The described effects exhibited
concentration-dependency. A further rise in duramycin
bath concentration (≥3.3 μM) induced a leak current con-
sistent with pore formation. The reported effects of
duramycin on ion channel function may be generated by
disruption of biophysical membrane properties rather
than by specific interaction with ion channel proteins.
Our data suggest that, under therapeutic conditions (i.e.
administration via inhalation), duramycin is unlikely to
elicit a QT-prolongation.
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